Open Access
CC BY-NC-ND 4.0 · Laryngorhinootologie 2018; 97(S 02): S106
DOI: 10.1055/s-0038-1640079
Abstracts
Onkologie: Oncology

Antibodies to tumor-associated antigens in head and neck squamous cell carcinoma patients differ by HPV-status

S Laban
1   Universitätsklinik Ulm, Klinik f. HNO & Kopf-Hals-Chirurgie, Ulm
,
D Gangkofner
1   Universitätsklinik Ulm, Klinik f. HNO & Kopf-Hals-Chirurgie, Ulm
,
L Schroeder
2   DKFZ, Abteilung Molekulare Diagnostik onkogener Infektionen (F020), Heidelberg
,
SB Eichmüller
3   DKFZ, GMP & T Cell Therapy Unit (G182), Heidelberg
,
M Broglie Däppen
4   Kantonsspital St. Gallen, Klinik für Hals-Nasen-Ohrenheilkunde und Kopf- Halschi, St. Gallen, Schweiz
,
G Dyckhoff
5   Universitätsklinik Heidelberg, Klinik für Hals-Nasen-Ohrenheilkunde und Kopf- Ha, Heidelberg
,
P Boscolo-Rizzo
6   Universitätsklinik Padua, Abteilung für Neurowissenschaften, Hals-Nasen-Ohrenhei, Treviso, Italien
,
G Wichmann
7   Universitätsklinik Leipzig, Klinik für Hals-Nasen-Ohrenheilkunde und Kopf- Halsc, Leipzig
,
M Pawlita
2   DKFZ, Abteilung Molekulare Diagnostik onkogener Infektionen (F020), Heidelberg
,
D Holzinger
2   DKFZ, Abteilung Molekulare Diagnostik onkogener Infektionen (F020), Heidelberg
› Author Affiliations
› Further Information
Also available ateRef
 
 

    Introduction:

    We have previously established an association of MAGE-/NY-ESO-1 expression and poor prognosis in head and neck squamous cell carcinoma (HNSCC) patients (pt). There is some evidence that TAA differ between HPV-negative (HPV-) and HPV-positive (HPV+) patients. Antibodies (AB) to tumor-associated antigens (TAA) may help to characterize the TAA repertoire in the tumor.

    Methods:

    AB to 29 auto-antigens and HPV-16 E6 were analyzed in serum and plasma samples of 410 HNSCC pt treated at different German cancer centers. As a surrogate marker, reactivity to HPV-16 E6 was used to define the HPV status. Statistical comparison of AB prevalence by HPV-status was performed using a Chi2 test corrected for multiple testing using the method of Benjamini, Krieger and Yekutieli with a false discovery rate of 10%.

    Results:

    Among 410 pt, 126 (31%) were reactive to HPV-16 E6. The five most frequent AB were directed against HPV-16 E6 (31%), MAGE-A3 (13%), SpanXa1 (12%), MAGE-A4 (11%) and MAGE-A1 (10%). In HPV-negative pt, AB against MAGE-A3, MAGE-A4, SpanXa1, LAGE-1a and NY-ESO-1 were detected in ≥10% of pt, whereas in HPV-positive pt AB against SpanXa1, CT-47 and MAGE-A1 were found in ≥10% of pt. Significant differences with regard to the prevalence of AB by HPV-status were detected for p53, MAGE-A3, -A4, -A9, LAGE-1a and NY-ESO-1 (p < 0.022).

    Conclusions:

    The prevalence of antigen-specific AB to TAA differed significantly by HPV-status. In the development of antigen-specific immunotherapy such as cancer vaccines, HPV status has to be acknowledged. Data analysis is ongoing.


     

    No conflict of interest has been declared by the author(s).

    Dr. med. Simon Laban
    Universitätsklinik Ulm, Klinik f. HNO & Kopf-Hals-Chirurgie,
    Frauensteige 12, 89070,
    Ulm

    Publication History

    Publication Date:
    18 April 2018 (online)

    © 2018. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    Georg Thieme Verlag KG
    Stuttgart · New York